All In Biotech

Drug Trial Radar · NCT03298867

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease

Last checked: Nov 20, 2026Latest source record: Jul 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

83

Actual

Start

Oct 4, 2017

Primary completion

Feb 13, 2019

Study completion Nov 30, 2020

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Oct 2, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective is to investigate the efficacy, tolerability, and safety of teprotumumab (a fully human monoclonal antibody \[mAb\] inhibitor of the insulin-like growth factor-1 receptor \[IGF-1R\]) administered once every 3 weeks (q3W) for 21 weeks with a final assessment at Week 24, in comparison to placebo, in the treatment of participants with moderate-to-severe active thyroid eye disease (TED).

Conditions

  • Thyroid Eye Disease
  • Graves' Orbitopathy

Interventions

  • TeprotumumabBiological

    Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).

  • PlaceboOther

    Placebo will consist of normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as would be appropriate, per weight-based dosing volumes (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Were Proptosis Responders at Week 24Time frame: Week 24

Locations

14 sites in 3 countries. Site status is shown where the registry gives one.

  • Macro, Llc

    Beverly Hills, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • The Lennar Foundation Medical

    Coral Gables, Florida

  • Bascom Palmer Eye Institute

    Miami, Florida

  • Kellogg Eye Center at University of Michigan

    Ann Arbor, Michigan

  • Casey Eye Institute at Oregon Health and Science University

    Portland, Oregon

  • Hamilton Eye Institute at University of Tennessee Health Science Center

    Memphis, Tennessee

  • Eye Wellness Center

    Houston, Texas

  • Medical College of Wisconsin, The Eye Institute

    Milwaukee, Wisconsin

  • University Hospital Essen, Department of Ophthalmology

    Essen, Germany

  • Johannes Gutenberg University Medical Center

    Mainz, Germany

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • University of Pisa, Department of Clinical and Experimental Medicine

    Pisa, Italy

  • University of Pisa,Department of Clinical and Experimental Medicine, Endocrinology Unit

    Pisa, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.